Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)

Korábbi kezelés

• Patients treated with chemo-immunotherapy associations
• Any CTCAE grade ≥3 immune-related adverse event observed within 3 weeks prior to CIRT start
• Patients treated with immunotherapy combinations (e.g. subjects treated with anti-CTLA4 + anti-PD1/PDL1 are excluded)
• Patients receiving immunotherapy within clinical trials
• Patients receiving off-label immunotherapy or within expanded access programs or as compassionate use
• Previous RT, regardless of energy, on the metastatic site selected to be irradiated

Más betegség

• Presence of metal prostheses or any other condition to prevent adequate imaging for identification of the target volume and calculation of the dose
• Loco-regional conditions not allowing hadron therapy (e.g. active infections in RT target region)
• Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness (e.g. infectious disease)
• Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
• Patients with autoimmune diseases (ADs), including local and systemic collagen-vascular (CVD) and inflammatory bowel diseases (IBD)

Egyéb

• Any immune-related CTCAE grade 4 adverse event, before study entry
• Prisoners or subjects who are involuntarily incarcerated
• Patients with high tumor burden defined as > 10 lesions and/or sum of diameters > 19 cm
• Patients with distant metastases only located in the CNS are excluded

• Signed written informed consent
• Histologic confirmation of malignancies under treatment with single agent anti-PD1/PDL1 immunotherapy per clinical practice (see cohort specific inclusion criteria) with immune checkpoint inhibitors approved by Italian national drug regulatory agencies (Agenzia Italiana del Farmaco, AIFA)
• Having a disease stability as assessed by AIFA monitoring sheet
• Presence of at least 2 measurable target lesions, of which at least one to be followed up as per RECIST and one suitable for CIRT
• Willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study
• Females and males, 18 years of age or older (no upper limit for age)
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Subjects must have measurable disease by CT or MRI per RECIST 1.1